We look forward to seeing you at the 6th Pharmacoepidemiology Research Network Symposium.
As with previous Symposia, this event will provide an opportunity to meet other colleagues who share an interest in the utilisation and safety of medicines, medical devices, and vaccines.
Delegates will include academic researchers, healthcare providers, and colleagues from relevant Ministries and other government-funded agencies.
Date: Tuesday, 23 November 2021
Venue: Seminar Room A/B, St David Lecture Theatre Complex, 70 St David Street, Dunedin (COVID-19 Alert Level(s) permitting, otherwise via videoconferencing)
We are delighted that three keynote speakers will be joining us to discuss aspects of COVID-19 vaccine safety monitoring:
Ms Julianne Gee, an epidemiologist from the United States Centers for Disease Control and Prevention who is currently serving as the Deputy Team Lead of the Vaccine Safety Team on the CDC’s COVID-19 Vaccine Task Force and as a senior technical advisor to the Global Immunization Safety Team.
Professor Michael Gold, a paediatric allergist and immunologist who has contributed to several World Health Organization vaccine safety guidelines and is a committee member of the Vaccine Safety Investigation Group (VSIG) of the Australian Therapeutic Goods Administration and of the AusVaxSafety Expert Advisory Group for Active Vaccine Surveillance.
Associate Professor Helen Petousis-Harris, a vaccinologist who previously chaired the World Health Organization’s Global Advisory Committee on Vaccine Safety (GACVS) and is currently an elected member of the Brighton Collaboration Science Board.
Representatives from Medsafe will also discuss the COVID-19 vaccine safety monitoring that is being undertaken in New Zealand.
Medsafe is the New Zealand Medicines and Medical Devices Safety Authority. We are responsible for the regulation of medicines and medical devices in New Zealand. We ensure that medicines and medical devices are acceptably safe.
PHARMAC is the New Zealand Government agency that decides which medicines and medical devices are subsidised, both in the community and in public hospitals. PHARMAC’s job is to ensure that New Zealanders get the best health outcomes from money the Government spends on pharmaceuticals, helping to keep our health system affordable. PHARMAC has a strong interest in engaging in and supporting research. Research, data, and analysis is important to PHARMAC to help with decision-making and continuing to get the best value it can from the funding provided.